Modeling Subpopulations with the $MIXTURE Subroutine in NONMEM: Finding the Individual Probability of Belonging to a Subpopulation for the Use in Model Analysis and Improved Decision Making
暂无分享,去创建一个
Andrew C. Hooker | Mats O. Karlsson | Kristin C. Carlsson | Radojka M. Savi | M. Karlsson | K. C. Carlsson | A. Hooker
[1] R. Morris,et al. Population Pharmacokinetics of Perhexiline From Very Sparse, Routine Monitoring Data , 2001, Therapeutic drug monitoring.
[2] B. Frame,et al. Population Pharmacokinetics of Ceftizoxime Administered by Continuous Infusion in Clinically Ill Adult Patients , 1998, Antimicrobial Agents and Chemotherapy.
[3] Y. Lee. Modeling and Simulations , 2011 .
[4] L Aarons,et al. Software for Population Pharmacokinetics and Pharmacodynamics , 1999, Clinical pharmacokinetics.
[5] R. Brasch,et al. Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability , 2005, Journal of magnetic resonance imaging : JMRI.
[6] Mats O Karlsson,et al. Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. , 2003, British journal of clinical pharmacology.
[7] Lynn McFadyen,et al. A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[8] Brian Corrigan,et al. Exposure‐response analysis of pregabalin add‐on treatment of patients with refractory partial seizures , 2003, Clinical pharmacology and therapeutics.
[9] A. Peer,et al. Galantamine Population Pharmacokinetics in Patients with Alzheimer's Disease: Modeling and Simulations , 2003, Journal of clinical pharmacology.
[10] S. Higuchi,et al. Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach. , 2006, Drug metabolism and pharmacokinetics.
[11] N. Holford,et al. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. , 2003, British journal of clinical pharmacology.
[12] Mats O. Karlsson,et al. Likelihood-Based Diagnostics for Influential Individuals in Non-Linear Mixed Effects Model Selection , 2004, Pharmaceutical Research.